Listing Kratom As Schedule I Will Impede Research Opportunities
The DEA’s plan to list kratom as a Schedule I controlled substance would make researching the possible opioid substitute much more difficult.
Treatment Guidelines
Cognition in Depression: A Critical Domain for Health Outcomes, Measurement, and Treatment
Dr. Roger McIntyre suggests that the clinical relevance of cognitive dysfunction for any individual patient can only be adjudicated on a case-by-case basis.
Next post in Depressive Disorder
